

# US Healthcare Provider Perspectives on the Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND)

Laurie Zografos,<sup>6</sup> Ashley Jean-Louis,<sup>6</sup> Cindy Garris<sup>5</sup>

<sup>1</sup>NYU Langone Health & AIDS Healthcare Foundation, New York, NY, USA; <sup>4</sup>Indiana University School of Medicine, Indianapolis, IN, USA; <sup>5</sup>ViiV Healthcare, Durham, NC, USA; <sup>6</sup>RTI Health Solutions, Research Triangle Park, NC, USA

## Key Takeaways

The perspectives of healthcare providers (HCPs) on implementing CAB + RPV long-acting (LA) injections in real-world clinics and practices were evaluated at baseline in the **BEYOND** study

Initial survey results indicate that HCPs had a positive overall opinion of CAB + RPV LA, with most finding CAB + RPV LA implementation to be easy, and multiple benefits of administering the regimen to people with HIV (PWH)

## Introduction

- CAB + RPV LA is the first complete long-acting regimen for maintenance of viral suppression in currently virologically suppressed people with HIV (PWH) and recommended by treatment guidelines<sup>1,2</sup>
- As an injectable regimen administered monthly or every 2 months by a healthcare provider (HCP), CAB + RPV LA may alleviate some challenges with daily oral therapy<sup>3</sup>
- Switching to CAB + RPV LA injections demonstrated non-inferiority vs continuing current daily oral antiretroviral therapy in clinical studies<sup>4,5</sup>
- Real-world perspectives are needed to enable successful delivery of this treatment in clinical practice within the US
- The BEYOND study aims to describe the perspectives and characteristics of HCPs and PWH implementing and initiating CAB + RPV LA treatment in US clinics and practices
- Here we describe the baseline survey results from HCPs at the time of site activation in the **BEYOND** study

## **Methods**

- BEYOND is a 2-year prospective, observational, real-world study of utilization, clinical outcomes, and experiences of HCPs and PWH initiating CAB + RPV LA across multiple US sites
- Participating sites were selected to maximize diversity in terms of geography, participant characteristics, practice type, payer source, and prior clinical research experience
- At the time of site activation (Sep 2021-Feb 2022) and prior to enrolling PWH in the study, HCPs at participating sites (physicians/treaters, injectors, and drug acquisition/reimbursement staff) completed surveys evaluating experiences to date with implementation of CAB + RPV LA in their clinics
- Follow-up surveys of HCPs are planned at 6, 12, and 24 months

# Results

## **Site Characteristics**


- HCPs from 24 sites responded to the initial survey (Figure 1)
- All clinics reported serving PWH with employer-sponsored commercial insurance (n=23/23); nearly all had PWH covered by Medicare or Medicaid (n=22/23 [96%] each), a Medicare-Medicaid Plan (n=19/23 [83%]), or the AIDS Drug Assistance Program (n=19/23 [83%]); 52% (n=12/23) of clinics reported serving uninsured PWH
- 25% (n=6/24) of clinics had 1-10 years of experience caring for PWH, 33% (n=8/24) had 11-20 years, and 42% (n=10/24) had >20 years of experience
- At the time of site survey completion, the number of PWH currently receiving CAB + RPV LA were: 1-10 PWH at 63% (n=15/24) of clinics, 11-25 at 21% (5/24), 26-50 at 13% (3/24), and 51-100 at 4% (n=1/24) of clinics


## **HCP-Estimated PWH Eligibility For CAB + RPV LA**

 75% (n=18/24) of HCPs estimated that at least 25% of PWH at their clinics are eligible and appropriate candidates for CAB + RPV LA

## IDWeek 2022; October 19-23, 2022; Virtual and Washington, DC

# Ricky Hsu,<sup>1</sup> John Phoenix,<sup>2</sup> Gary Sinclair,<sup>3</sup> Samir Kumar Gupta,<sup>4</sup> Ana Puga,<sup>5</sup> Kaitlin Nguyen,<sup>5</sup> Cathy Schubert,<sup>5</sup> Deanna Merrill,<sup>5</sup> Paula Teichner,<sup>5</sup> David Richardson,<sup>6</sup> Kate Nelson,<sup>6</sup> Maria Reynolds,<sup>6</sup>





### HCP Perspectives on Administering and Implementing CAB + RPV LA

- The majority (n=19/24 [79%]) of HCPs reported they were extremely/very positive about administering CAB + RPV LA
- Over 90% of injectors reported a positive overall opinion about administering CAB + RPV LA, and 86% (n=18/21) reported the injections were easy to administer
- Few HCPs overall reported significant concerns about potential barriers to successful CAB + RPV LA implementation. Reimbursement and insurance coverage were the barriers of most concern, with 25% (n=6/24) and 29% (n=7/24) of HCPs, respectively, expressing extreme concern (Figure 3)

Acknowledgments: This study was funded by ViiV Healthcare. Editorial assistance and graphic design support for this poster were provided under the direction of the authors by MedThink SciCom and funded by ViiV Healthcare.

References: 1. Cabenuva [prescribing information]. ViiV Healthcare; 2021. 2. Panel on Antiretroviral Guidelines for Adults and Adolescents. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescentarv/guidelines-adult-adolescent-arv.pdf. Accessed August 22, 2022. 3. Kerrigan et al. PLoS One. 2018;13:e0190487. 4. Swindells et al. N Engl J Med. 2020;382:1112-1123. 5. Orkin et al. N Engl J Med. 2020;382:1124-1135.

extremely (59%, n=10/17), very (18%, n=3/17), or somewhat (18%, n=3/17) helpful • Over 95% (n=23/24) of sites have patient reminder systems (Figure 5)

- One clinic (4.3%) allowed patients to decide how often they received appointment reminders before their visit; other clinics sent either 1 (n=1/23 [4%]), 2 (n=11/23 [48%]), or 3 (n=10/23 [43%]) reminders
- 74% (n=17/23) of clinics send a reminder 2-3 days prior to an appointment and 61% (n=14/23) of clinics send a reminder 1 day prior; only 13% (n=3/23) send a reminder 4-7 days prior
- 92% (n=22/24) of sites have a system in place to identify missed injection visits, 86% (n=19/22) of which identify missed injection visits by manually reviewing patient records or appointments





n (%)	Sites (N=24)
e of patient ART adherence	16 (67)
re more engaged with their HIV treatment	15 (63)
discuss patient concerns at injection visits	11 (46)
address and optimize management of other patient care needs due to more risits	10 (42)
ask patients about their experience or concerns with their HIV treatment	9 (38)
HIV is better controlled	7 (29)
fewer ART prescription refills for CAB + RPV LA patients	4 (17)
	2 (8)
	2 (8)

- Early real-world data from US HCPs in the BEYOND study indicates interest in and anticipated uptake of CAB + RPV LA at their sites, positive overall opinion, and multiple benefits of administering the CAB + RPV LA regimen to PWH
- At this early stage of real-world implementation, insurance and reimbursement issues are the main sources of concern for providers
- Many providers believe their patients would be eligible to receive CAB + RPV LA and that setting up appointments and administering injections would be easy
- The perceived benefits of HCP-administered CAB + RPV LA as directly observed therapy included PWH having higher engagement with treatment and assurance of greater treatment adherence